| Literature DB >> 25258477 |
Jui-Chi Tsai1, Yi-Wen Lin2, Chun-Yao Huang3, Feng-Yen Lin3, Chien-Sung Tsai4.
Abstract
Human platelets express Toll-like receptors (TLR) 4. However, the mechanism by which TLR4 directly affects platelet aggregation and blood coagulation remains to be explored. Therefore, in this study, we evaluated the platelet TLR4 expression in patients who underwent CABG surgery; we explored the correlation between platelet TLR4 expression and the early outcomes in hospital of patients. Additionally, C57BL/6 and C57BL/6-Tlr(LPS-/-) mice were used to explore the roles of platelet TLR4 in coagulation by platelet aggregometry and rotation thromboelastometry. In conclusion, our results highlight the important roles of TLR4 in blood coagulation and platelet function. Of clinical relevance, we also explored novel roles for platelet TLR4 that are associated with early outcomes in cardiac surgery.Entities:
Mesh:
Substances:
Year: 2014 PMID: 25258477 PMCID: PMC4167458 DOI: 10.1155/2014/484510
Source DB: PubMed Journal: Mediators Inflamm ISSN: 0962-9351 Impact factor: 4.711
Preoperative characteristics in CABG surgery patients.
| CABG surgery with conventional CPB | CABG surgery with off-pump technique | |
|---|---|---|
| Total number | 17 | 6 |
| Age (years) | 63.1 ± 10.1 | 61.5 ± 12.7 |
| Body weight (kg) | 69.3 ± 11.4 | 71.7 ± 14.5 |
| Body height (cm) | 162.3 ± 8.9 | 163.3 ± 9.2 |
| Smoke (%) | 23.5 | 50.0 |
| Diabetes mellitus (%) | 11.7 | 0 |
| Hypertension (%) | 64.7 | 66.7 |
| Hypercholesterolemia (%) | 82.4 | 83.3 |
| COPD (%) | 11.8 | 16.7 |
| Stroke (%) | 0 | 16.7 |
| Peripheral vascular disease (%) | 5.9 | 0 |
| Prior myocardial infarction (%) | 0 | 16.7 |
| Ejection fraction (%) | 59.7 ± 9.2 | 63.5 ± 8.3 |
COPD: chronic obstructive pulmonary disease. The values are shown as the mean ± SD.
Perioperative characteristics in CABG surgery patients.
| CABG surgery with | CABG surgery with | |
|---|---|---|
| Total number | 17 | 6 |
| CPB time (min) | 119.1 ± 12.4 | — |
| Aortic clamping time (min) | 65.6 ± 5.2 | — |
| Minimal esophageal temperature (°C) | 26.1 ± 0.4 | 35.8 ± 0.3* |
| Heparin (units) | 30476.2 ± 1708.0 | 28142.9 ± 4532.6 |
| Number of grafts | 3.1 | 2.5 |
CPB time indicates duration of CPB ischemia plus the duration of aortic cross clamping. The values are shown as the mean ± SD. *P < 0.05 compared with the group receiving CABG surgery with conventional CPB.
Biochemical analyses in elective CABG patients.
| Parameter | CABG surgery with conventional CPB ( | CABG surgery with off-pump technique ( | ||
|---|---|---|---|---|
| Presurgery | Postsurgery | Presurgery | Postsurgery | |
| Blood (postsurgery: end of surgery) | ||||
| Neutrophil (%) | 60.9 ± 9.2 | 85.9 ± 3.6* | 64.7 ± 8.0 | 86.2 ± 4.3* |
| Eosinophil (%) | 4.0 ± 2.6 | 2.1 ± 0.1 | 2.0 ± 1.4 | 2.2 ± 0.1 |
| Basophil (%) | 0.4 ± 0.3 | 0.5 ± 0.1 | 0.4 ± 0.2 | 0.5 ± 0.1 |
| Monocyte (%) | 6.4 ± 1.5 | 6.4 ± 1.9 | 6.7 ± 1.3 | 6.8 ± 1.6 |
| Lymphocyte (%) | 28.3 ± 9.2 | 7.5 ± 3.2* | 26.1 ± 7.7 | 6.8 ± 2.7* |
| Platelet (×109/L) | 230.1 ± 91.1 | 111.2 ± 25.0* | 188.8 ± 34.2 | 200.5 ± 22.5 |
|
| ||||
| Kidney function (postsurgery: after surgery for 24 h) | ||||
| BUN | 17.4 ± 5.2 | 22.2 ± 8.1 | 17.5 ± 3.5 | 16.3 ± 4.5 |
| Creatinine (mg/dL) | 1.0 ± 0.4 | 3.0 ± 1.4 | 1.1 ± 0.3 | 1.3 ± 0.4 |
|
| ||||
| Liver function (postsurgery: after surgery for 24 h) | ||||
| AST | 25.0 ± 10.1 | 39.7 ± 15.0 | 33.7 ± 13.2 | 42.0 ± 9.1 |
| ALT | 20.5 ± 13.5 | 22.6 ± 12.6 | 28.2 ± 13.7 | 33.2 ± 13.5 |
|
| ||||
| Myocardial damage (postsurgery: after surgery for 24 h) | ||||
| CK-MB/CK (%) | 6.0 ± 3.2 | 4.7 ± 2.9 | 7.6 ± 5.5 | 4.1 ± 1.6 |
| CK-MB (mg/dL) | 22.9 ± 11.2 | 29.8 ± 13.9 | 22.7 ± 11.2 | 28.3 ± 7.5 |
| Troponin I (mg/L) | 1.0 ± 0.9 | 2.9 ± 2.0* | 1.1 ± 1.6 | 1.6 ± 1.6 |
|
| ||||
| Inflammation (postsurgery: after surgery for 24 h) | ||||
| CRP (mg/L) | 3.1 ± 2.7 | 5.5 ± 2.0 | 2.9 ± 2.8 | 5.6 ± 0.5 |
BUN: blood urea nitrogen; AST: glutamate oxaloacetate transaminase; ALT: glutamic pyruvic transaminase; CRP: C-reactive protein. The values are the mean ± SD. *P < 0.05 compared with presurgery at the same group.
TLR4 expression, drainage, duration of ICU stay, and duration of fever in CABG surgery patients.
| CABG surgery with conventional CPB | CABG surgery with off-pump technique |
| |
|---|---|---|---|
| Total number | 17 | 6 | |
| TLR4 expression (% of preincision) | 68.5 ± 5.6 | 89.0 ± 4.8 | <0.05 |
| Drainage (mL) | 786.1 ± 84.8 | 534.7 ± 79.9 | <0.001 |
| pRBC transfusion (unit) | 5.0 ± 0.5 | 1.1 ± 1.1 | 0.001 |
| Platelet transfusion (unit) | 1.3 ± 0.4 | — | — |
| ICU stay (day) | 4.4 ± 2.5 | 2.8 ± 2.0 | 0.171 |
| ICU fever (hr) | 23.5 ± 14.7 | 14.5 ± 7.6 | 0.173 |
ICU: intensive care unit. The values are shown as the mean ± SD. P < 0.05 was considered statistically significant.
Figure 1CABG surgery with conventional CPB decreases calpain activity in platelets. (a) Total protein was isolated from washed platelets collected from patients who underwent the off-pump technique. The western blot results demonstrate the calpain activity before and after CABG surgery. (b) Total protein isolated from washed platelets collected from patients who underwent conventional CPB. The western blot results demonstrate the calpain activity before and after CABG surgery.
Calpain activity correlates with TLR4 expression and blood loss in postoperative CABG patients.
| Calpain-1 expression after surgery | CABG surgery with conventional CPB | CABG surgery with off-pump technique |
G1 versus G2 |
G1 versus G3 |
G2 versus G3 | ||
|---|---|---|---|---|---|---|---|
| G1: active | G2: inactive | G3: active | G4: inactive | ||||
| TLR4 expression (% of preincision) | 83.92 ± 6.14 | 48.4 ± 19.3 | 89.0 ± 4.8 | — | <0.05 | 0.157 | <0.001 |
| Drainage loss (mL) | 528.0 ± 39.8 | 841.4 ± 96.7 | 534.7 ± 79.9 | — | <0.05 | 0.897 | <0.001 |
| pRBC transfusion (unit) | 3.5 ± 0.9 | 5.0 ± 1.0 | 1.1 ± 1.1 | — | 0.442 | 0.160 | 0.031 |
| Platelet transfusion (unit) | 0.9 ± 0.2 | 3.3 ± 2.3 | 0 | — | 0.001 | 0.008 | <0.001 |
| ICU stay (day) | 2.3 ± 0.3 | 4.9 ± 0.7 | 2.8 ± 2.0 | — | 0.001 | 0.690 | <0.001 |
| ICU fever (hr) | 16.3 ± 6.6 | 25.0 ± 4.1 | 14.5 ± 7.6 | — | 0.008 | 0.739 | <0.05 |
TLR4: Toll-like receptor; pRBC: packed red blood cell; ICU: intensive care unit. The values are shown as the mean ± SD. P < 0.05 was considered statistically significant.
Figure 2Platelet TLR4 is associated with platelet function in C57BL/6 mice. (a) TLR4 protein expression on the surface of platelets in C57BL/6 and C57BL/6-Tlr mice was analyzed by western blot analysis (upper graph) and flow cytometry (button graph). Negative control analyses were performed in the absence of specific PE-conjugated anti-TLR4 antibody (gray outline-hollow graph). C57BL/6 mice (black graph), but not C57BL/6-Tlr mice (black outline-hollow graph), express TLR4 protein in platelets. (b) Platelet aggregation was analyzed using aggregometry. The upper graph shows C57BL/6, C57BL/6-Tlr , and C57BL/6-Tlr mouse platelets with 0.1 U/mL thrombin or PBS treatment. The data at the bottom illustrate the mean ± SD (n = 6). *P < 0.05 indicates a significant difference compared with the C57BL/6 group. (c and d) ROTEM was performed. The thromboelastometry graph shows the curves of EXTEM (c) and FIBTEM (d) in C57BL/6 (black line) and C57BL/6-Tlr (red line) mice.
ROTEM measurements of EXTEM in experimental mice.
| Parameters | C57BL/6 ( | C57BL/6- | C57BL/6- |
|---|---|---|---|
| Coagulation activation and clot polymerization parameters | |||
| Coagulation time (seconds) | 31.00 ± 22.16 | 33.50 ± 18.27 | 30.67 ± 10.61 |
| Clot formation time (seconds) | 38.33 ± 9.61 | 44.00 ± 3.16 | 39.67 ± 7.63 |
|
| 82.17 ± 2.04 | 78.17 ± 6.05 | 82.0 ± 1.55 |
|
| |||
| Clot firmness parameters (mm) | |||
| Amplitude at 5 min (A5) | 59.33 ± 8.02 | 47.67 ± 7.15* | 55.67 ± 5.28 |
| A10 | 66.00 ± 6.63 | 56.17 ± 5.74* | 62.67 ± 4.32 |
| A15 | 69.00 ± 5.73 | 60.17 ± 5.23* | 65.83 ± 4.17 |
| A20 | 70.83 ± 5.34 | 62.17 ± 5.23* | 67.67 ± 3.67 |
| A25 | 71.83 ± 4.83 | 63.83 ± 5.00* | 69.00 ± 3.52 |
| A30 | 72.83 ± 4.83 | 64.83 ± 5.00* | 69.67 ± 7.63 |
| Maximum clot firmness (MCF) | 74.67 ± 4.08 | 67.33 ± 4.97* | 72.33 ± 2.16 |
ROTEM: rotation thromboelastometry; EXTEM: extrinsically activated assay using recombinant tissue factor.
The data are expressed as the median (interquartile range).*P < 0.05 compared with the C57BL/6 group.
ROTEM measurements of FIBTEM in experimental mice.
| Parameters | C57BL/6 ( | C57BL/6 | C57BL/6- |
|---|---|---|---|
| Coagulation activation and clot polymerization parameters | |||
| Coagulation time (seconds) | 19.83 ± 4.67 | 17.50 ± 6.89 | 12.83 ± 6.31* |
|
| 76.00 ± 7.56 | 78.50 ± 6.92 | 80.17 ± 2.32 |
|
| |||
| Clot firmness parameters (mm) | |||
| Amplitude at 5 min (A5) | 14.33 ± 4.37 | 15.33 ± 4.59 | 17.76 ± 3.20 |
| A10 | 15.33 ± 4.63 | 16.50 ± 5.58 | 19.33 ± 3.14 |
| A15 | 16.50 ± 4.51 | 17.17 ± 5.53 | 20.67 ± 3.20* |
| A20 | 17.17 ± 4.36 | 17.67 ± 5.79 | 21.50 ± 3.33* |
| A25 | 17.50 ± 4.46 | 17.67 ± 5.79 | 21.83 ± 3.06* |
| A30 | 17.67 ± 6.11 | 17.83 ± 5.74 | 22.33 ± 3.20* |
| Maximum clot firmness (MCF) | 18.33 ± 5.09 | 18.00 ± 6.26 | 23.33 ± 4.13* |
ROTEM: rotation thromboelastometry; FIBTEM: extrinsically activated test using recombinant tissue factor with cytochalasin D. The data are expressed as the median (interquartile range). *P < 0.05 compared with the C57BL/6 group.
The platelet component of clot strength in experimental mice.
| C57BL/6 ( | C57BL/6- | C57BL/6- | |
|---|---|---|---|
| Maximum clot firmness (MCF) | 58.80 ± 4.67 | 48.80 ± 3.27* | 48.50 ± 3.00* |
| Maximum clot elasticity (MCE) | 290.85 ± 10.99 | 190.89 ± 20.79* | 218.37 ± 19.54* |
The platelet component of clot strength was calculated using the following equation: MCFplatelet = MCFEXTEM − MCFFIBTEM; MCE = (MCF × 100)/100 − MCF; MCEplatelet = MCEEXTEM − MCEFIBTEM.*P < 0.05 compared with the C57BL/6 group.